Latest H5N1 clinical trials Stories
VIENNA, Austria, January 13 /PRNewswire/ -- - By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010 - The Positive Results Obtained in the Previous Clinical Phase I Study will be Published in the Renowned "Journal of Infectious Diseases" on 15 January 2010 AVIR Green Hills Biotechnology, the...
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China. No vaccine or antiviral...
Accelerated approval process used in vaccine approvalThe U.S. Food and Drug Administration this week approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Annual vaccination remains the best protection from influenza, particularly for people 65 and...
One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal.Initial reports of 2009 influenza A(H1N1) infection in many countries have largely involved children, especially those attending school. Reports have also indicated high hospitalization rates of children younger than 5...
LYON, France and SWIFTWATER, Pa., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is expanding its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the United States. The trial started in the United Kingdom earlier this year. The incidence of CDI has increased significantly in recent years in both North America and Europe. CDI-related treatments in these two regions of the...
The European Medicines Agency announced that young children who are receiving GlaxoSmithKline's H1N1 vaccine may contract a fever after the second injection. In a statement was released Friday, and the European drug controller added that statistics pulled from GlaxoSmithKline PLC indicated a large amount of children from six months to 3 years contracted a fever after the second dose of the vaccine. Other side effects reported included muscle discomfort, sleepiness, and irritability. The...
ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries. In Stage A of this study,...
BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan. Under this purchase order, Sinovac is required to produce an additional one million doses of PANFLU.1 (TM) (15ug/0.5ml) for the Chinese central government. The delivery...
ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal...
The WHO said on Tuesday that GlaxoSmithKline recalled a batch of swine flu vaccine in Canada after a number of severe allergic reactions surfaced, The Associated Press reported.The recall was issued after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal, according to company spokeswoman Gwenan White.White said GlaxoSmithKline advised health care professionals not to use the batch while health authorities investigate.However, the batch in...
